- Home
- OTLY vs CERS Comparison
OTLY vs CERS Comparison
Compare OTLY & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- CERS
- Stock Information
- Founded
- OTLY 1994
- CERS 1991
- Country
- OTLY Sweden
- CERS United States
- Employees
- OTLY N/A
- CERS N/A
- Industry
- OTLY Packaged Foods
- CERS EDP Services
- Sector
- OTLY Consumer Staples
- CERS Technology
- Exchange
- OTLY Nasdaq
- CERS Nasdaq
- Market Cap
- OTLY 395.7M
- CERS 347.3M
- IPO Year
- OTLY 2021
- CERS 1997
- Fundamental
- Price
- OTLY $7.95
- CERS $1.65
- Analyst Decision
- OTLY Buy
- CERS Buy
- Analyst Count
- OTLY 4
- CERS 3
- Target Price
- OTLY $1.20
- CERS $3.17
- AVG Volume (30 Days)
- OTLY 312.6K
- CERS 1.6M
- Earning Date
- OTLY 02-12-2025
- CERS 02-20-2025
- Dividend Yield
- OTLY N/A
- CERS N/A
- EPS Growth
- OTLY N/A
- CERS N/A
- EPS
- OTLY N/A
- CERS N/A
- Revenue
- OTLY $823,666,000.00
- CERS $180,270,000.00
- Revenue This Year
- OTLY $9.21
- CERS $15.95
- Revenue Next Year
- OTLY $7.02
- CERS $10.50
- P/E Ratio
- OTLY N/A
- CERS N/A
- Revenue Growth
- OTLY 5.15
- CERS 15.29
- 52 Week Low
- OTLY $6.00
- CERS $1.38
- 52 Week High
- OTLY $26.80
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- OTLY 33.58
- CERS 41.40
- Support Level
- OTLY $6.00
- CERS $1.64
- Resistance Level
- OTLY $10.90
- CERS $1.96
- Average True Range (ATR)
- OTLY 1.40
- CERS 0.11
- MACD
- OTLY -0.28
- CERS -0.02
- Stochastic Oscillator
- OTLY 30.95
- CERS 3.12
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.